Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Ropinirole

Criteria

Inclusion Criteria:

• Males or non-pregnant/non-breast feeding females

• At least 30 years of age

• Diagnosis of idiopathic Parkinson''s disease (Hoehn & Yahr criteria)

• Completed either Study 167 or Study 164

Exclusion Criteria:

• Presence of uncontrolled psychiatric, hematological, renal, hepatic,endocrinological, neurological, cardiovascular disease or active malignancy

• Dizziness or fainting due to orthostatic hypotension on standing

• Significant sleep disorder

• Drug abuse or alcoholism